Curis Lifesciences IPO [Initial Public Offering] is a book build issue of 21,50,000 shares [₹27.52 crore]. The issue is a combination of a fresh issue of 21,50,000 shares [₹27.52 crore].
The Curis Lifesciences IPO will open for subscription on November 07, 2025, and close on November 11, 2025. The Curis Lifesciences IPO allotment is expected to be finalized on November 12, 2025, while the Curis Lifesciences IPO are scheduled to be listed on the NSE and SME on November 14, 2025.
The price band for the Curis Lifesciences IPO is fixed at ₹120 to ₹128 per share. The minimum application size is 2 lots [2,000 shares], requiring a retail investor to invest at least ₹2,56,000 [based on the upper price band]. For S-HNI investors, the minimum application size is 3 lots [3,000 shares] worth ₹3,84,000, while for B-HNI investors, it is 8 lots [8,000 shares] worth ₹10,24,000.
Curis Lifesciences IPO Details
| Open Date | November 07, 2025 |
| Close Date | November 11, 2025 |
| Issue Type | Book Built Issue |
| Face Value | ₹10 Equity Share |
| Price Band | ₹120 – ₹128 Per Share |
| Listing On | NSE, SME |
| Issue Size | ₹27.52 Cr. [21,50,000 Shares] |
| Fresh Issue | ₹27.52 Cr. [21,50,000 Shares] |
| Offer For Sale | Not Applicable |
| Prospectus | DRHP | RHP | Anchor Investors |
Curis Lifesciences IPO Anchor Investors Details
| Anchor Bid Date | November 06, 2025 |
| Anchor Portion Size | ₹7.81 Cr. |
| Share Offered | 6,10,000 Shares |
| Anchor lock-in period end date for 50% shares [30 Days] | December 12, 2025 |
| Anchor lock-in period end date for remaining shares [90 Days] | February 10, 2026 |
Curis Lifesciences IPO Reservation
| Category | Reservation | Shares Offered |
|---|---|---|
| QIB | 47.35% | 10,18,000 |
| NII | 14.33% | 3,08,000 |
| RII | 33.30% | 7,16,000 |
| Market Maker | 5.02% | 1,08,000 |
| Total | 100.00% | 21,50,000 |
Curis Lifesciences IPO Market Lot
| Application | Lot | Shares | Amount |
| Retail Minimum | 2 | 2,000 | ₹2,56,000 |
| Retail Maximum | 2 | 2,000 | ₹2,56,000 |
| S-HNI Minimum | 3 | 3,000 | ₹3,84,000 |
| S-HNI Maximum | 7 | 7,000 | ₹8,96,000 |
| B- HNI Minimum | 8 | 8,000 | ₹10,24,000 |
Key Performance Indicator
| KPI | Value |
| Market Capitalisation | ₹103.48 Cr. |
| P/E Ratio | 12.44x |
| EPS | ₹10.29 |
| ROE | 55.25% |
| ROCE | 27.83% |
| RoNW | 37.62% |
| Dept/Equity | 0.96 |
| EBITDA Margin | 19.41% |
| PAT Margin | 12.43% |
| Net Assets Value | ₹27.34 Per Equity Share |
| Price To Book Value | ₹12.64 |
Curis Lifesciences IPO No Peer Comparison
| Company | P/E | EPS | RoNW | NAV |
| N/A | — | — | — | — |
Curis Lifesciences IPO Dates
| Open Date | November 07, 2025 |
| Close Date | November 11, 2025 |
| Allotment Date | November 12, 2025 |
| Refund Date | November 13, 2025 |
| Share Credit Date | November 13, 2025 |
| Listing Date | November 14, 2025 |
Curis Lifesciences Company Financial Report
| Years | Assets | Income | Expenses | Net Worth | PAT | Borrow |
|---|---|---|---|---|---|---|
| July 2025 | ₹56.29 Cr. | ₹19.51 Cr. | ₹15.79 Cr. | ₹19.10 Cr. | ₹2.87 Cr. | ₹15.32 Cr. |
| March 2025 | ₹42.53 Cr. | ₹49.65 Cr. | ₹41.38 Cr. | ₹16.23 Cr. | ₹6.11 Cr. | ₹15.62 Cr. |
| March 2024 | ₹33.88 Cr. | ₹35.87 Cr. | ₹28.70 Cr. | ₹5.87 Cr. | ₹4.87 Cr. | ₹17.09 Cr. |
| March 2023 | ₹29.75 Cr. | ₹36.42 Cr. | ₹34.23 Cr. | ₹1.01 Cr. | ₹1.88 Cr. | ₹16.19 Cr. |
Company Promoters :
- Mr. Dharmesh Dashrathbhai Patel
- Mr. Siddhant Jayantibhai Pawasia
- Mr. Piyush Gordhanbhai Antala
- Mr. Jaimik Mansukhbhai Patel
| Holding Pre Issue | 92.68% | 59,34,434 Shares |
| Holding Post Issue | 68.03% | 80,84,434 Shares |
Curis Lifesciences IPO Lead Managers
- Finaax Capital Advisors Private Limited
Curis Lifesciences IPO Registrar
MUFG Intime India Private Limited
Address: C- 101, 247 Park, L B S Marg, Vikhroli West, Mumbai -400083, Maharashtra;
Tel No.: +91 810 811 4949;
Email Id: curislifesciences.smeipo@in.mpms.mufg.com
Website: https://www.in.mpms.mufg.com/
About The Company
Curis Lifesciences Limited, established in 2010, is a growing pharmaceutical company dedicated to developing, manufacturing, and marketing a wide range of healthcare products for both domestic and international markets. The company operates through loan license and contract manufacturing models while also promoting its own branded formulations in select regions.
With over a decade of experience, Curis Lifesciences has built strong partnerships, serving more than 100 corporate clients under loan or contract manufacturing arrangements, along with marketing its in-house brands in countries like Yemen and Kenya. The company’s diverse product portfolio includes general tablets, capsules, oral liquids, external formulations, and sterile ophthalmic ointments, catering to multiple therapeutic areas.
Operating from a cutting-edge manufacturing facility located in Sanand, Gujarat, Curis Lifesciences ensures the highest standards of quality and safety through rigorous testing and advanced production practices. Backed by a team of 95 skilled professionals as of July 2025, the company continues to expand its reach by leveraging its experienced leadership, strategic manufacturing base, and scalable business model focused on quality and innovation.
Objects Of The Issue
- Capital Expenditure towards Upgradation/Improvement of the existing Manufacturing Facilities
- Capital Expenditure towards Construction of a Storage Facility
- Pre-payment/Repayment of outstanding Secured Loans
- Product Registrations in other countries
- Funding our Working Capital Requirements
- General Corporate Purposes
Company Address
Curis Lifesciences Limited
PF-23, GIDC Sanand – II,
Industrial Estate,
Sanand
Ahmedabad, Gujarat, 382110
Phone: +91 99045 22543
Email: cs@curisls.com
Website: https://curisls.com/
Curis Lifesciences IPO FAQs
What are the open and close dates of the Curis Lifesciences IPO?
The Curis Lifesciences IPO will open on November 07, 2025 and will close on November 11, 2025.
What is the price band for Curis Lifesciences IPO?
The price band for the Curis Lifesciences IPO is fixed at ₹120 to ₹128 per share.
What is the lot size of the Curis Lifesciences IPO?
Investors can apply for a minimum of 2,000 shares per lot and in multiples thereafter.
How can retail investors apply for the Curis Lifesciences IPO?
Retail investors can apply through UPI-based ASBA (Application Supported by Blocked Amount) via their bank or stock broker’s platform.
What is the issue size of the Curis Lifesciences IPO?
The total issue size of Curis Lifesciences IPO is ₹27.52 Cr., comprising both fresh issue and offer for sale (if applicable).
When will the basis of allotment for the Curis Lifesciences IPO be finalized?
The Curis Lifesciences IPO allotment is expected to be finalized on November 12, 2025.
How can I check the allotment status of the Curis Lifesciences IPO?
Investors can check their allotment status on the official registrar’s website once it is announced.
When will the shares of Curis Lifesciences IPO get listed?
The Curis Lifesciences IPO to be listed on the NSE and SME on November 14, 2025.
Is the Curis Lifesciences IPO a good investment?
Investment decisions depend on an individual’s financial goals and risk profile. It is advised to consult with a SEBI-registered financial advisor before making any investment decision.
| Read Also |
|---|
| Curis Lifesciences IPO GMP |
| Curis Lifesciences IPO Subscription |
| Curis Lifesciences IPO Allotment |
Disclaimer: Readers are strongly advised to seek guidance from a qualified financial advisor before making any investment decisions. Relying solely on the content presented here for financial choices is done entirely at the reader’s own risk.
| Thank You… |
|---|